US patent awarded to Biognosys

Biognosys announces that a core patent from ETH Zurich which is exclusively licensed to Biognosys was granted in the US (US8501421 B2) and the corresponding application is pending in Europe. The patent describes a method for efficient development of SRM/MRM assays using, for example, synthetic peptide libraries. 

With increasing demand for quantitative multiplexed proteomics the development and validation of assays becomes a bottleneck. This patent enables Biognosys to protect a key process in high-content targeted proteomics experiments. 

Biognosys’ “targeted proteomics” can quantify proteins from any biological sample with unbeatable precision and speed. The solution is based on a novel mass spectrometric technology that allows simultaneous measurement of thousands of proteins in one sample and subsequent storage of the full information in a digital protein map.

The revolutionary feature of Biognosys’ HRM-MS™ technology is that it allows quantifying proteins retrospectively. It means that one physical measurement of a sample is sufficient for any future analysis of proteins that were present in the sample. This innovative concept of a Digital Biobank will revolutionize clinical research and diagnostics. The company was founded in 2008 and is located in Schlieren.